EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201

PartnershipEPY201Positive

AI Analysis

Summary

EpilepsyGTx and Viralgen announced a collaboration to scale AAV manufacturing for EPY201, a gene therapy candidate, to support preparation for first-in-human clinical trials.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.60

gene therapyAAV manufacturingpartnershipEPY201first-in-human trialmanufacturing scale-up

Related Companies

$TRAX

Read the original article

Published by PharmaTimes on September 17, 2026 9:00 AM

Read Original